Tung M. Fong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tung M. Fong has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
A. Galijatovic‐Idrizbegovic
Department of Safety Assessment, Merck Research Laboratories, West Point, PA 19486
1 shared publicationA.C. Huber
Department of Safety Assessment, Merck Research Laboratories, West Point, PA 19486
1 shared publicationA.M. Strack
Department of Pharmacology, Merck Research Laboratories, Rahway, NJ 07065
1 shared publicationC. DeMaula
Department of Safety Assessment, Merck Research Laboratories, West Point, PA 19486
1 shared publicationC.L. Lanning
Department of Safety Assessment, Merck Research Laboratories, West Point, PA 19486
1 shared publicationC.R.‐R. Huang
Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065
1 shared publication
Latest Publications
- 14 July 2009
- Published by Springer Nature in International Journal of Obesity
- Vol. 33 (9) , 947-955
Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions
Rimonabant and taranabant are two extensively studied cannabinoid-1 receptor (CB1R) inverse agonists. Their effects on in vivo peripheral tissue metabolism are generally well replicated. The central nervous system site of action of taranabant or rimonabant is firmly established based on brain receptor occupancy studies. At the whole-body level, the mechanism of action of CB1R inverse agonists includes a reduction in food intake and an increase in energy expenditure. At the tissue level, fat mass reduction, liver lipid reduction and improved insulin sensitivity have been shown. These effects on tissue metabolism are readily explained by CB1R inverse agonist acting on brain CB1R and indirectly influencing the tissue metabolism through the autonomic nervous system. It has also been hypothesized that rimonabant acts directly on adipocytes, hepatocytes, pancreatic islets or skeletal muscle in addition to acting on brain CB1R, although strong support for the contribution of peripherally located CB1R to in vivo efficacy is still lacking. This review will carefully examine the published literature and provide a perspective on what new tools and studies are required to address the peripheral site of action hypothesis.
- 14 July 2009
- Published by Springer Nature in International Journal of Obesity
- Vol. 33 (9) , 947-955
Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions
Rimonabant and taranabant are two extensively studied cannabinoid-1 receptor (CB1R) inverse agonists. Their effects on in vivo peripheral tissue metabolism are generally well replicated. The central nervous system site of action of taranabant or rimonabant is firmly established based on brain receptor occupancy studies. At the whole-body level, the mechanism of action of CB1R inverse agonists includes a reduction in food intake and an increase in energy expenditure. At the tissue level, fat mass reduction, liver lipid reduction and improved insulin sensitivity have been shown. These effects on tissue metabolism are readily explained by CB1R inverse agonist acting on brain CB1R and indirectly influencing the tissue metabolism through the autonomic nervous system. It has also been hypothesized that rimonabant acts directly on adipocytes, hepatocytes, pancreatic islets or skeletal muscle in addition to acting on brain CB1R, although strong support for the contribution of peripherally located CB1R to in vivo efficacy is still lacking. This review will carefully examine the published literature and provide a perspective on what new tools and studies are required to address the peripheral site of action hypothesis.
- 22 June 2009
- Published by Wiley in Drug Development Research
- Vol. 70 (5) , 349-362
Pharmacological efficacy and safety profile of taranabant in preclinical species
Taranabant is a highly selective and potent cannabinoid CB1receptor inverse agonist. We compared the pharmacological properties of taranabant with another inverse agonist, rimonabant, and determined the preclinical safety margins of taranabant. In vitro studies demonstrated that taranabant is ∼10‐fold more potent than rimonabant at the CB1receptor, and taranabant is more selective based on off‐target in vitro screening. In vivo efficacy studies demonstrated that taranabant is ∼10‐fold more potent than rimonabant in diet‐induced obese rats. In repeat‐dose toxicological studies, taranabant did not cause mortality in rodents and monkeys at exposure margins ≤6478 and 1922 times the estimated human exposure at 0.5 mg/day−1. Taranabant did not produce CNS signs, including seizures, when administered to monkeys for 1 year at 10 mg/kg−1day−1(highest dose tested chronically), corresponding to an exposure margin of 974 times. In contrast to primates, taranabant produced brief handling‐induced seizure‐like activity in rodents, species predisposed to handling‐induced seizures. Throughout the entire preclinical program, taranabant did not cause histopathological changes in the peripheral or central nervous system. In summary, the highly selective nature of taranabant is consistent with its generally favorable preclinical safety profile. Drug Dev Res 2009.
- 22 June 2009
- Published by Wiley in Drug Development Research
- Vol. 70 (5) , 349-362
Pharmacological efficacy and safety profile of taranabant in preclinical species
Taranabant is a highly selective and potent cannabinoid CB1receptor inverse agonist. We compared the pharmacological properties of taranabant with another inverse agonist, rimonabant, and determined the preclinical safety margins of taranabant. In vitro studies demonstrated that taranabant is ∼10‐fold more potent than rimonabant at the CB1receptor, and taranabant is more selective based on off‐target in vitro screening. In vivo efficacy studies demonstrated that taranabant is ∼10‐fold more potent than rimonabant in diet‐induced obese rats. In repeat‐dose toxicological studies, taranabant did not cause mortality in rodents and monkeys at exposure margins ≤6478 and 1922 times the estimated human exposure at 0.5 mg/day−1. Taranabant did not produce CNS signs, including seizures, when administered to monkeys for 1 year at 10 mg/kg−1day−1(highest dose tested chronically), corresponding to an exposure margin of 974 times. In contrast to primates, taranabant produced brief handling‐induced seizure‐like activity in rodents, species predisposed to handling‐induced seizures. Throughout the entire preclinical program, taranabant did not cause histopathological changes in the peripheral or central nervous system. In summary, the highly selective nature of taranabant is consistent with its generally favorable preclinical safety profile. Drug Dev Res 2009.